April 2023: Using the body’s immune system to fight cancer cells is the goal of the promising cancer treatment method known as tumour infiltrating lymphocytes (TIL) immunotherapy. The process entails taking immune cells called TILs out of a patient’s tumour tissue, growing and activating them outside the body, and then returning them into the patient. By increasing the amount of immune cells that can identify and kill cancer cells, this therapy aims to reduce or completely eradicate tumours.
White blood cells known as TILs are an essential component of the body’s immune response against malignancies. Although these cells can identify and target cancer cells, their efficacy may be compromised in patients with advanced cancer. TILs are isolated from a patient’s tumour tissue sample and used in TIL therapy. To improve their capacity to identify and combat cancer cells, these cells are then cultivated in the lab and activated by signalling molecules such as cytokines.
The TILs are reintroduced into the patient’s body via infusion after being grown and activated. The TILs move to the tumor’s location and start attacking cancer cells there. It is hoped that by raising the body’s TIL levels, the immune system will be better able to combat cancer.
A number of solid tumours, including melanoma, cervical cancer, and ovarian cancer, have responded favorably to TIL therapy in clinical trials. There have been instances where the cancer has completely disappeared. To fully comprehend the therapy’s potential and constraints, additional research is required as it is still in the early phases of development.
Finding the precise TILs that attack cancer cells most effectively is one of the biggest challenges of TIL therapy. TILs’ widespread application may be constrained by their complexity and length of time-consuming extraction, expansion, and activation processes. To address these issues, researchers are looking into ways to accelerate the TIL extraction and activation procedure and to provide more individualised, targeted treatments.
Overall, TIL therapy is a promising method for treating cancer that has produced good outcomes in preliminary clinical trials. The potential advantages of this therapy make it an interesting field of research for the future of cancer treatment, despite the fact that there are still numerous obstacles to be solved.
TILs therapy in India
Some of the leading oncologists in India has started TILs therapy with the help of foreign collaborations. Several types of solid tumor cases like melanoma, sarcomas, gynec cancers, GI cancers can be cured with the help of TILs therapy.
Cost of TILs therapy in India
Cost of TILs therapy in India depends upon the type of cancer and overall tumor burden on the patient. It highly case dependent. For details of cost please send patients medical reports to info@cancerfax.com or connect on WhatsApp to +91 96 1588 1588.
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. His career is marked by significant contributions to stem cell biology, developmental biology, and innovative research techniques.
Research Highlights
Dr. Mittal's research has focused on several key areas:
1) Cardiovascular Development and Regeneration: He studied coronary vessel development and regeneration using zebrafish models1.
2) Cancer Biology: At Dartmouth College, he developed zebrafish models for studying tumor heterogeneity and clonal evolution in pancreatic cancer.
3) Developmental Biology: His doctoral work at Keio University involved identifying and characterizing medaka fish mutants with cardiovascular defects.
4) Stem Cell Research: He investigated the effects of folic acid on mouse embryonic stem cells and worked on cryopreservation techniques for hematopoietic stem cells.
Publications and Presentations
Dr. Mittal has authored several peer-reviewed publications in reputable journals such as Scientific Reports, Cardiovascular Research, and Disease Models & Mechanisms1. He has also presented his research at numerous international conferences, including the Stanford-Weill Cornell Cardiovascular Research Symposium and the Weinstein Cardiovascular Development Conference.
In summary, Dr. Nishant Mittal is a dedicated and accomplished researcher with a strong track record in cardiovascular and cancer biology, demonstrating expertise in various model systems and a commitment to advancing scientific knowledge through innovative research approaches.
